Hospital
ST. Luke's Hospital- Easton Campus
ST. Luke's Hospital- Easton Campus was paid $8.79M by Medicaid between Jan 2018 and Dec 2024, across 137 billing codes. Its largest line is 99283, emergency room visit (moderate) — 30% of everything it billed.
33Billing provider infoST. LUKE'S HOSPITAL- EASTON CAMPUS
EASTON, PA 18042
EASTON, PA 18042
33aNPI1073047981assigned 04/18/2017
33bProvider typeGeneral Acute Care Hospital
28Total paid$8.79M
24GClaims157,440
24DCodes billed137
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Pennsylvania
Rank by total paid#36 of 154
Median peer was paid$2.82M
This provider vs. median3.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 871 | $52K | |
| 2019 | 3,979 | $96K | |
| 2020 | 13,200 | $474K | |
| 2021 | 65,989 | $3.77M | |
| 2022 | 27,323 | $1.70M | |
| 2023 | 26,081 | $1.53M | |
| 2024incomplete | 19,997 | $1.16M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 30% | 19,008 | 18,270 | $2.60M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 27% | 27,352 | 24,687 | $2.35M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 18% | 10,917 | 10,461 | $1.57M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.1% | 4,008 | 3,793 | $535K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 4.2% | 3,218 | 3,186 | $367K |
| G0378 | Hospital observation service, per hour | 2.8% | 383 | 344 | $248K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.0% | 2,875 | 2,782 | $176K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.6% | 4,068 | 3,904 | $142K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.4% | 762 | 731 | $119K |
| 80053 | Comprehensive metabolic panel | 1.1% | 10,420 | 9,789 | $101K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 13,308 | 12,374 | $65K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 5,183 | 4,766 | $54K |
125 more codes
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 4,793 | $38K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 757 | $37K |
| 80050 | General health panel | <1% | 765 | $31K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 504 | $27K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 112 | $21K |
| 71045 | Radiologic examination, chest; single view | <1% | 3,302 | $20K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 386 | $19K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,812 | $14K |
| X0616 | <1% | 86 | $13K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 203 | $13K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 32 | $13K |
| 80061 | Lipid panel | <1% | 911 | $11K |
| 83880 | <1% | 368 | $10K | |
| 83735 | <1% | 1,563 | $10K | |
| 83690 | <1% | 2,067 | $10K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 249 | $9K |
| 87631 | <1% | 48 | $7K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 666 | $6K |
| 81001 | <1% | 2,491 | $6K | |
| 84484 | <1% | 1,045 | $6K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 211 | $6K |
| M0239 | Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring | <1% | 23 | $6K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 352 | $5K |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 13 | $5K |
| 87040 | <1% | 303 | $5K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 249 | $5K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 249 | $5K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 336 | $5K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 190 | $5K |
| 73630 | <1% | 454 | $4K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 172 | $4K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 104 | $4K |
| 85379 | <1% | 412 | $4K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 600 | $4K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 192 | $4K |
| OP250 | <1% | 1,821 | $3K | |
| 83605 | <1% | 570 | $3K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 3,318 | $3K |
| 86803 | <1% | 167 | $3K | |
| 84702 | <1% | 167 | $3K | |
| 81003 | <1% | 985 | $2K | |
| 84703 | <1% | 244 | $2K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 51 | $2K |
| 85730 | <1% | 507 | $2K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 378 | $2K |
| 85027 | <1% | 376 | $2K | |
| 85610 | <1% | 729 | $2K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 148 | $2K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 27 | $2K |
| 73610 | <1% | 135 | $2K | |
| 80076 | <1% | 140 | $2K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 13 | $2K |
| 70498 | <1% | 14 | $2K | |
| 70496 | <1% | 13 | $1K | |
| 73130 | <1% | 151 | $1K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 56 | $1K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 547 | $1K |
| 71250 | <1% | 27 | $1K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 16 | $992.40 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 112 | $938.19 |
| 87186 | <1% | 120 | $900.00 | |
| 87077 | <1% | 116 | $846.27 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,614 | $836.35 |
| 82805 | <1% | 28 | $832.38 | |
| 87070 | <1% | 118 | $813.15 | |
| 82550 | <1% | 125 | $741.12 | |
| 82728 | <1% | 59 | $618.00 | |
| 85007 | <1% | 170 | $567.49 | |
| 82948 | <1% | 362 | $525.54 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 423 | $520.39 |
| 73564 | <1% | 45 | $471.90 | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 28 | $444.31 |
| 73030 | <1% | 55 | $427.91 | |
| 73140 | <1% | 33 | $422.76 | |
| 76801 | <1% | 14 | $418.98 | |
| J3490 | Unclassified drugs | <1% | 132 | $367.57 |
| 84145 | <1% | 25 | $363.83 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,364 | $343.74 |
| 83540 | <1% | 49 | $339.89 | |
| 90715 | <1% | 49 | $332.17 | |
| 82077 | <1% | 102 | $323.16 | |
| 82570 | <1% | 45 | $296.06 | |
| 82803 | <1% | 19 | $286.66 | |
| 82043 | <1% | 37 | $263.71 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 40 | $218.70 |
| 84439 | <1% | 28 | $218.24 | |
| 84153 | <1% | 12 | $213.40 | |
| 86140 | <1% | 79 | $204.43 | |
| 81025 | <1% | 161 | $186.47 | |
| 86592 | <1% | 42 | $175.47 | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,392 | $166.20 |
| 86901 | <1% | 46 | $163.88 | |
| 86900 | <1% | 46 | $161.95 | |
| 82607 | <1% | 12 | $149.35 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,438 | $148.79 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 447 | $127.91 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 41 | $118.77 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 732 | $117.57 |
| 82330 | <1% | 19 | $113.29 | |
| 83550 | <1% | 25 | $83.40 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 138 | $78.78 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 705 | $71.61 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 647 | $69.01 |
| 87088 | <1% | 13 | $64.00 | |
| 84295 | <1% | 15 | $61.88 | |
| 87081 | <1% | 16 | $61.25 | |
| 84132 | <1% | 16 | $60.35 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 16 | $59.04 |
| 85014 | <1% | 19 | $37.87 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 668 | $37.00 |
| 87205 | <1% | 13 | $36.36 | |
| 82947 | <1% | 17 | $33.28 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 13 | $19.40 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 448 | $5.08 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 69 | $0.01 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 97 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 29 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 15 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 14 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 335 | $0.00 |
| G0471 | Collection of venous blood by venipuncture or urine sample by catheterization from an individual in a skilled nursing facility (snf) or by a laboratory on behalf of a home health agency (hha) | 0% | 59 | $0.00 |
| 96375 | Therapeutic injection; each additional sequential IV push | 0% | 42 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 72 | $0.00 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 0% | 17 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 21 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBOTEK, FRANCINE (SENIOR VP FINANCE)
| Provider | Location | Paid |
|---|---|---|
| ST Luke's Hospital | Lehighton, PA | $638K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.